Candel Therapeutics, Inc. Debt-to-equity in % from Q1 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Candel Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q3 2025.
  • Candel Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 29.2 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

Candel Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 29.2 +1.98K Sep 30, 2025
Q2 2025 52.9 -316 -85.7% Jun 30, 2025
Q1 2025 117 -33.3 -22.2% Mar 31, 2025
Q4 2024 295 +191 +182% Dec 31, 2024
Q3 2024 -1.95K -2.03K -2547% Sep 30, 2024
Q2 2024 369 +299 +430% Jun 30, 2024
Q1 2024 150 +87.9 +142% Mar 31, 2024
Q4 2023 105 +44.7 +74.7% Dec 31, 2023
Q3 2023 79.7 +26 +48.4% Sep 30, 2023
Q2 2023 69.5 +18.1 +35.2% Jun 30, 2023
Q1 2023 62 -19.7 -24.2% Mar 31, 2023
Q4 2022 59.9 Dec 31, 2022
Q3 2022 53.7 Sep 30, 2022
Q2 2022 51.4 Jun 30, 2022
Q1 2022 81.7 Mar 31, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.